1. HOME
  2. ABOUT US
    About Laekna Core Management Team Board of Directors Milestones Scientific Advisory Board Honors & Awards
  3. R&D
    R&D Therapeutic Areas Core Products Pipeline Clinical Trials
  4. PARTNERSHIPS
    Strategic Partners Business Development Holistic Approach BD Contact
  5. INVESTORS
    Investors IR Contact
  6. NEWS
    Press Releases Media Coverage
  7. CAREERS
    Global Team Career Development Jobs My Laekna
  8. CONTACT US
    Contact Us Leave Message
  9. RSS Feeds
 ABOUT US
GROUND-BREAKING THERAPEUTICS

Founded in 2016,

we are a clinical-stage biotechnology company

Learn More
Operation Team
Research & Development Team
in China and the US
 ABOUT US
GROUND-BREAKING THERAPEUTICS

Founded in 2016,

we are a clinical-stage biotechnology company

Learn More
Research & Development Team
in China and the US
Zhangjiang Pharma Valley, Shanghai, China
New Jersey, USA
Operation Team
Lingang, Shanghai
R&D
LEADING INNOVATION

Committed to bringing

novel therapies to

cancer and liver fibrosis patients worldwide


More in the pipeline

  1. 15

    innovative product

    candidates

  2. 6

    clinical

    trials

  3. including3

    multi-regional clinical trials

    (MRCTs)

  4. including1

    registrational

    clinical trial

NEWS
LATEST ARTICLES
Learn More
  1. 2023-01-06
    Laekna Therapeutics will be attending the 41st Annual J.P. Morgan Healthcare Conference
    More
  2. 2022-09-05
    Laekna Announces First Patient Dosed in South Korea in LAE201INT2101 Phase 1/2 Study
    More
  3. 2022-07-31
    Laekna and Innovent Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy
    Learn More
    2022-05-26
    Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
    Learn More
NEWS
LATEST ARTICLES
Learn More
  1. 2023-01-06
    Laekna Therapeutics will be attending the 41st Annual J.P. Morgan Healthcare Conference
    More
  2. 2022-09-05
    Laekna Announces First Patient Dosed in South Korea in LAE201INT2101 Phase 1/2 Study
    More
  3. 2022-07-31
    Laekna and Innovent Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy
    More
CAREERS
OUR PEOPLE
Join Us
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Positions

Follow us on Linkedin

  1. HOME
  2. ABOUT US
  3. R&D
  4. PARTNERSHIPS
  5. INVESTORS
  6. NEWS
  7. CAREERS
  8. CONTACT US

Copyright © Laekna Therapeutics, All Rights Reserved.  Privacy Policy

Follow us on Linkedin

Follow us on Wechat